Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 19/10/2026			5-day change	1st Jan Change
5.030 ^USD	+0.60%		-8.55%	-1.95%

10-20	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT
10-20	Alvotech Shares Rise After FDA Okays Simlandi Manufacturing Process	DJ

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

69c22.hO_Kpvg_oPgsmkPN6MriywOVZOWupX9irKQHKEBG15Y.sYuJ6ptO85dh0y6LsYCznDDTUtOb7Ao67fZPTHIXrqPb2ILyiVDEsgHLGg~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

10-20	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT
09-16	Alvotech Shares Rise After Double Upgrade From Barclays	MT
09-16	Barclays Upgrades Alvotech to Overweight From Underweight, Adjusts PT to $8 From $4	MT
08-24	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
08-24	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
03-24	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
03-24	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
12-22	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
11-18	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
11-04	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
11-03	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
11-03	Top Premarket Decliners	MT
11-03	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
11-02	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
14/10/25	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/10/25	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
23/09/25	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/09/25	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/07/25	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/07/25	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
25/07/24	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24/05/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
22/03/24	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+43.14%
	WUXI APPTEC CO., LTD.					+30.97%
	LONZA GROUP AG					+13.23%
	ARGENX SE					+38.42%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+17.91%
	REVOLUTION MEDICINES, INC.					+41.56%
	CELLTRION, INC.					+35.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+9.2%
	Average					+26.75%
	Weighted average by Cap.					+25.83%